[EN] SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE [FR] INHIBITEURS À PETITES MOLÉCULES DE L'UBIQUITINE LIGASE CRL4
摘要:
Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1 expression or activity for the treatment or prevention of cancer, DNA damage, or related conditions. In some aspects, the interaction between CUL4A and/or CUL4B and the beta-propeller B of DDB1 is disrupted with the compounds, compositions, or methods.
[EN] SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE [FR] INHIBITEURS À PETITES MOLÉCULES DE L'UBIQUITINE LIGASE CRL4
摘要:
Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1 expression or activity for the treatment or prevention of cancer, DNA damage, or related conditions. In some aspects, the interaction between CUL4A and/or CUL4B and the beta-propeller B of DDB1 is disrupted with the compounds, compositions, or methods.
A highly general, convenient, and inexpensive catalyst system was developed for the N-arylation of sulfonamides with aryl iodides or bromides by using 5–20 mol % of CuI as catalyst, 20 mol % of N-methylglycine (for aryl iodides) or N,N-dimethylglycine (for arylbromides) as ligand, and K3PO4 as base.
高度通常,方便,廉价的催化剂体系用于将显影Ñ通过使用5-20%(摩尔)的CuI作为催化剂的,20摩尔%的与芳基碘化物或溴化物磺胺-arylation Ñ -methylglycine(为芳基碘化物)或ñ,N-二甲基甘氨酸(对于芳基溴化物)为配体,K 3 PO 4为碱。
[EN] SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE L'UBIQUITINE LIGASE CRL4
申请人:[en]CORNELL UNIVERSITY
公开号:WO2023173136A2
公开(公告)日:2023-09-14
Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1 expression or activity for the treatment or prevention of cancer, DNA damage, or related conditions. In some aspects, the interaction between CUL4A and/or CUL4B and the beta-propeller B of DDB1 is disrupted with the compounds, compositions, or methods.